Heron Posts Q3 Revenue of $35.3M, Down 7.8%, as CorMedix Asset Sale Looms
HRTX sits 45% above its 52-week low of $0.261.
Summary
Heron reported Q3 2026 net revenue of $35.3 million, down 7.8% year-over-year, with $23.4 million in cash, in the same 8-K cycle as its $145 million cash asset sale to CorMedix.
Key Events · Earnings and Guidance · HRTX
-
Q3 Revenue Falls 7.8%
Total net revenue was $35.3 million versus $38.2 million in Q3 2025 and $37.7 million in Q2 2026.
-
Acute Care Grows, Oncology Shrinks
Acute Care rose 22.5% year-over-year to $15.1 million on ZYNRELEF ($10.6 million, +13.8%) and APONVIE ($4.5 million, +49.3%); Oncology fell 22.2% to $20.1 million as CINVANTI dropped 16.6% and SUSTOL fell 92.0%.
-
Thin Cash Against Large Debt
The company ended the quarter with $23.4 million in cash, cash equivalents and short-term investments, against $91.6 million of non-current notes payable and $34.4 million of convertible notes.
-
Loss Narrows, Adjusted EBITDA Positive
Q3 net loss was $5.0 million versus $17.5 million a year ago; Adjusted EBITDA was $3.7 million versus $1.5 million.
Analysis · HRTX · Life Sciences
Q3 revenue fell 7.8% to $35.3 million as CINVANTI slid 16.6% and SUSTOL wound down, offset partly by 22.5% Acute Care growth. The company held just $23.4 million in cash against $126 million of notes payable, which is why the $145 million cash asset sale to CorMedix matters more than the quarter itself. Guidance remains withdrawn, and no conference call was held. The deal still needs a stockholder vote and customary closing conditions.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HRTX was trading at $0.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $55.6M. The 52-week trading range was $0.26 to $1.58. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.